Real-World Experience in Tricuspid Transcatheter Edge-to-Edge Repair: Transcatheter Tricuspid Valve Repair in Spain Registry
Por:
Sisinni, A, Barreiro-Perez, M, Freixa, X, Arzamendi, D, Moñivas, V, Carrasco-Chinchilla, F, Pan, M, Nombela-Franco, L, Pascual, I, Benito-González, T, Perez, R, Gómez-Blázquez, I, Amat-Santos, IJ, Cruz-González, I, Sánchez-Recalde, A, Alvarez, ABC, Sanchis, L, Caneiro-Queija, B, Li, CH, del Trigo, M, Martínez-Carmona, JD, Mesa, D, Pozo, E, Avanzas, P, Cepas-Guillén, P, Estévez-Loureiro, R
Publicada:
21 ene 2025
Resumen:
Background: Significant tricuspid regurgitation (TR) is associated with increased morbidity and mortality. The development of transcatheter valve repair therapies has opened a wide range of opportunities for treatment of patients with high surgical risk. Real-world data might improve patient selection and outcome. The authors sought to investigate acute and short-term cardiovascular outcomes of tricuspid transcatheter edge-to-edge repair (T-TEER) with dedicated devices in a real-world setting. Methods and Results: This is a retrospective, single-arm, multicenter registry conducted at 15 sites in Spain. The primary end point was a composite of all-cause death, rehospitalization for heart failure, and tricuspid valve re-intervention. Patients included (n=283) were older (76 +/- 9 years, 70% female), and showed significant comorbidities. Massive or torrential TR was present in 55% of subjects, with secondary cause being the main mechanism of regurgitation in approximate to 80% of individuals. Intraprocedural success was achieved in 79% of patients. At 1-year follow-up, significant improvements in TR grade (>= 3+, 100% to 25%, P <0.001) and New York Heart Association functional class (I/II, 33%-86%, P <0.001) were observed. Lead-induced cause and single leaflet device attachment emerged as independent predictors of at least severe predischarge residual TR. In-hospital mortality occurred in 4 (1.4%) patients, whereas the Kaplan-Meier estimated 1-year primary end point occurrence rate was 21%. Intraprocedural success (hazard ratio, 0.353 [95% CI, 0.156-0.798]; P=0.012), was found to be an independent predictor of primary end point. Conclusions: In a real-world contemporary setting, tricuspid transcatheter edge-to-edge repair with dedicated devices emerged as effective therapeutic option for patients with severe TR.
Filiaciones:
Sisinni, A:
Univ Hosp Alvaro Cunqueiro, Dept Cardiol, C Clara Campoamor 341, Vigo 36213, Spain
IRCCS Policlin San Donato, Dept Cardiol, Milan, Italy
Univ Vigo, Univ Hosp Alvaro Cunqueiro, Galicia Sur Hlth Res Inst IIS Galicia Sur, Dept Cardiol,Cardiovasc Res Grp,Serv Galego Saude, Vigo, Spain
Barreiro-Perez, M:
Univ Hosp Alvaro Cunqueiro, Dept Cardiol, C Clara Campoamor 341, Vigo 36213, Spain
Univ Vigo, Univ Hosp Alvaro Cunqueiro, Galicia Sur Hlth Res Inst IIS Galicia Sur, Dept Cardiol,Cardiovasc Res Grp,Serv Galego Saude, Vigo, Spain
Freixa, X:
Hosp Clin Barcelona, Cardiovasc Inst, Barcelona, Spain
Arzamendi, D:
Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Dept Dermatol, Barcelona, Spain
Moñivas, V:
Hosp Univ Puerta Hierro Majadahonda, Madrid, Spain
Carrasco-Chinchilla, F:
Univ Malaga UMA, Hosp Univ Virgen Victoria, Unidad Gest Clin Corazon, CIBERCV,Inst Invest Biomed Malaga IBIMA, Malaga 29010, Spain
Pan, M:
Univ Cordoba, Hosp Reina Sofia, Dept Cardiol, Inst Maimonides Invest Biomed Cordoba IMIBIC, Cordoba, Spain
Nombela-Franco, L:
IdISSC, Hosp Clin San Carlos, Cardiovasc Inst, Madrid, Spain
Pascual, I:
Hosp Univ Cent Asturias, Heart Area, Oviedo, Spain
Benito-González, T:
Univ Hosp Leon, Dept Cardiol, Leon, Spain
Perez, R:
Univ Hosp A Coruna, La Coruna, Spain
Gómez-Blázquez, I:
Univ Hosp 12 Octubre, Dept Cardiol, Madrid, Spain
Amat-Santos, IJ:
CIBERCV, Univ Clin Hosp, Dept Cardiol, Valladolid, Spain
Cruz-González, I:
Univ Hosp Salamanca, CIBERCV, Dept Cardiol, Salamanca, Spain
Sánchez-Recalde, A:
Hosp Univ Ramon y Cajal, Madrid, Spain
Alvarez, ABC:
CIBERCV, Univ Clin Hosp, Dept Cardiol, Santiago De Compostela, Spain
Sanchis, L:
Hosp Clin Barcelona, Cardiovasc Inst, Barcelona, Spain
Caneiro-Queija, B:
Univ Hosp Alvaro Cunqueiro, Dept Cardiol, C Clara Campoamor 341, Vigo 36213, Spain
Univ Vigo, Univ Hosp Alvaro Cunqueiro, Galicia Sur Hlth Res Inst IIS Galicia Sur, Dept Cardiol,Cardiovasc Res Grp,Serv Galego Saude, Vigo, Spain
Li, CH:
Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Dept Dermatol, Barcelona, Spain
del Trigo, M:
Hosp Univ Puerta Hierro Majadahonda, Madrid, Spain
Martínez-Carmona, JD:
Univ Malaga UMA, Hosp Univ Virgen Victoria, Unidad Gest Clin Corazon, CIBERCV,Inst Invest Biomed Malaga IBIMA, Malaga 29010, Spain
Mesa, D:
Univ Cordoba, Hosp Reina Sofia, Dept Cardiol, Inst Maimonides Invest Biomed Cordoba IMIBIC, Cordoba, Spain
Pozo, E:
IdISSC, Hosp Clin San Carlos, Cardiovasc Inst, Madrid, Spain
Avanzas, P:
Hosp Univ Cent Asturias, Heart Area, Oviedo, Spain
Cepas-Guillén, P:
Hosp Clin Barcelona, Cardiovasc Inst, Barcelona, Spain
Estévez-Loureiro, R:
Univ Hosp Alvaro Cunqueiro, Dept Cardiol, C Clara Campoamor 341, Vigo 36213, Spain
Univ Vigo, Univ Hosp Alvaro Cunqueiro, Galicia Sur Hlth Res Inst IIS Galicia Sur, Dept Cardiol,Cardiovasc Res Grp,Serv Galego Saude, Vigo, Spain
Green Submitted, gold
|